Large, contemporary cohorts (e.g., NIH RECOVER) report a ~31% higher risk of Long COVID in females—with age, pregnancy, and menopausal status shaping risk— underscoring the need for mechanistic, sex‑aware research and clinical translation.
UK statistics similarly show higher self‑reported prevalence and greater activity limitation among women, highlighting societal and economic burdens.
Mechanistically, converging evidence points to immune dysregulation (including altered monocyte/B‑cell states and low cortisol), autonomic dysfunction (e.g., orthostatic tachycardia/POTS), and endocrine perturbations, with plausible hormonal modulation of immune pathways.
Recent multi‑omic analyses suggest sex‑specific immune correlates and sustained inflammatory signalling in Long COVID, but integrated models linking symptoms to objective biomarkers across systems are rare.
This project will execute a three‑part programme: Outputs will delineate sex‑specific mechanisms, inform clinical triage (e.g., POTS screening), and identify candidate therapeutic targets, advancing both mechanistic insight and service design for women’s health in infection‑associated chronic illness.
94% of Loughborough’s research impact is rated world-leading or internationally excellent. REF 2021